783 related articles for article (PubMed ID: 16191301)
1. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
2. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions].
Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276
[TBL] [Abstract][Full Text] [Related]
3. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
Chen R; Zhang AR; Zhao XX; Li ZH
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
[TBL] [Abstract][Full Text] [Related]
4. [Changes of P-selectin and E-selectin in children with Kawasaki disease].
Qiu Y; Wu J; Fang XY; Lin Z; Wu BY; Cai RY; Xu XY; Zheng H
Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):688-92. PubMed ID: 15482673
[TBL] [Abstract][Full Text] [Related]
5. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
6. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
7. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis.
Matsuyama T
Pediatr Int; 1999 Jun; 41(3):239-45. PubMed ID: 10365570
[TBL] [Abstract][Full Text] [Related]
8. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.
Gavin PJ; Crawford SE; Shulman ST; Garcia FL; Rowley AH
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):576-81. PubMed ID: 12692003
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
[TBL] [Abstract][Full Text] [Related]
10. Abnormal matrix remodeling in adolescents and young adults with Kawasaki disease late after onset.
Lin MT; Chen SJ; Ho YL; Huang KC; Chen CA; Chiu SN; Sun LC; Lee WJ; Chen HC; Wang JK; Wu MH
Clin Chem; 2008 Nov; 54(11):1815-22. PubMed ID: 18801939
[TBL] [Abstract][Full Text] [Related]
11. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y
Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease.
Park JA; Shin KS; Kim YW
J Korean Med Sci; 2005 Aug; 20(4):607-11. PubMed ID: 16100452
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 942 cases of Kawasaki disease].
Zhang W; Li Q; Zhao XD; Tang XM; Wang XG; Wang M; Wu DQ; Ou Q; Yang XQ
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):324-8. PubMed ID: 16780705
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
16. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
Palus M; Zampachová E; Elsterová J; Růžek D
J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
[TBL] [Abstract][Full Text] [Related]
18. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
20. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
Kitoh T; Ohara T; Muto T; Okumura A; Baba R; Koizumi Y; Yamagishi Y; Mikamo H; Daigo K; Hamakubo T
Front Immunol; 2021; 12():624802. PubMed ID: 33912155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]